Edina, MN, September 03, 2015 --(PR.com
)-- The world’s leading experts in the fields of pain and migraine research will be meeting in Washington, DC on September 23-24, 2015 for the 9th Annual Pain & Migraine Therapeutics Summit. This conference will provide attendees with thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products.
Wendy Niebler, DO, MBA, Senior VP of Clinical Development and Medical Affairs at Egalet will be discussing recent clinical development of abuse-deterrent opioids since April 2015, when the U.S. FDA released a finalized guidance on evaluation and labeling for abuse-deterrent opioids. She will emphasize various ways that clinical development will be affected by the new finalized guidance.
Also speaking at the Summit this year will be Robert H. Dworkin, Ph.D., Professor of Anesthesiology, Neurology, and Psychiatry at the University of Rochester School of Medicine and Dentistry. His presentation will focus on false positive/negative results of analgesic clinical trials, and why they occur. He will explain what can be done to optimize the design of clinical trials to reduce false positive and false negative trial outcomes from occurring.
David Upmalis, MD, Senior Director, Compound Development Team Leader, fulranumab, Janssen Research and Development will update attendees on his company’s development of fulranumab, a human monoclonal anti-NGF that is being tested for its efficacy in treating the painful symptoms of osteoarthritis as well as other types of pain. NGF antagonists have had a somewhat checkered clinical past, but with an FDA hold on their clinical development recently lifted, pain researchers and physicians are excited about their clinical potential. Dr. Upmalis will review clinical data to date, provide an update on the drug’s regulatory status as well as detail future clinical plans for fulranumab.
The Summit is also pleased to announce the inclusion of Ernesto Aycardi, MD, Senior Director Clinical Development, Migraine & Headaches, Teva Pharmaceuticals in this year’s agenda. His presentation will focus on the clinical development program for TEV 48125, an anti-CGRP therapy for Migraine. With successful clinical findings in phase 2, he will present recent clinical data, including how disrupting CGRP signaling has shown to be efficacious in the acute treatment of migraine.
Please visit 9th Annual Pain & Migraine Therapeutics Summit for the full list of speakers, the agenda and information on how to register to attend.
Arrowhead's conferences are about far more than just presentations; our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. For more information on our various conferences, visit www.arrowheadpublishers.com